EN DE
Watch Innocare Pharma Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Innocare Pharma Ltd (9969) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Innocare Pharma Ltd stock HK$10.42, price HK$11.09, that is 6.0% below the price, quality 76 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG4783B1032

IP Innocare Pharma Ltd logo Broad data Nov 14, 2026

Innocare Pharma Ltd

9969 · HK

Strong company, but the stock is already about fairly priced and falling price: meets 1 of 3 rules.

Get notified free when this changes
Quality 76/100 
Highly profitable · 40.6% net margin (TTM) 
Low debt 
Generates free cash flow 
Ranks above peers (11/14) 
Broad data 
Fair value HK$10.42 · Fairly valued 
Expensive Growth (revenue 5y +341.9 %/yr in CNY) 
Wide moat 77/100 · thin data
Falling price (downtrend) 
Watch Innocare Pharma Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$30.65 HK$4.06 Fair Value HK$10.42 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range HK$4.06 – HK$30.65 · fair‑value band HK$7.75 – HK$12.82 · the HK$11.09 price screens above the HK$10.42 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Innocare Pharma in your weekly email

Every Wednesday you see whether Innocare Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.

Show moreShow less

The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder.

It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor.

InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.

Stock analysis

Innocare Pharma Ltd (9969) currently trades at HK$11.09, while our model-based Fair Value estimate is HK$10.42, so the stock looks roughly fairly valued today (gap 6.4%).

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$22.89 per share, and 13 of the 26 models we run sit above the HK$11.09 price.

Bear case: the Asset-Based group reads lowest at HK$3.91, and 13 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: HK$7.75 (bear) to HK$12.82 (bull), the price of HK$11.09 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 76/100 (high quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Innocare Pharma Ltd reported revenue of 2.3B CNY in FY2025 versus 1.0B CNY in FY2021, a compound +21.8%/yr. Reported net income was 626M CNY in FY2025.

Key figures

Market cap HK$19.6B (≈ $2.5B) Mid · P/E ratio 19.1 · P/S ratio 8.62 · EPS (TTM) HK$0.8689 · Dividend yield 0.2% · Net margin 40.6% · Return on equity 18.3% · Return on assets (EBIT) −3.6% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 77 out of 100 (low confidence).

What moves the price

The share trades about 30% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −6%, 9969 screens cheaper than that median.

Fair Value models

Bear HK$7.75 Fair Value HK$10.42 Bull HK$12.82
Price HK$11.09 · Downside -6.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then (HK$0.7642 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$7.16 HK$8.52 HK$12.86 78
Growth DCF HK$7.02 HK$9.22 HK$12.82 77
EPV HK$7.76 HK$8.25 HK$8.69 74
All 26 models by family
DCF Models
FCF DCF HK$7.16 HK$8.52 HK$12.86 78
Owner Earnings HK$9.12 HK$14.65 HK$26.27 71
5Y Revenue Exit HK$7.99 HK$10.71 HK$16.45 70
5Y EBITDA Exit HK$8.90 HK$12.57 HK$19.77 72
5Y P/E Exit HK$11.57 HK$21.45 HK$35.17 66
10Y Revenue Exit HK$7.66 HK$12.00 HK$15.04 65
10Y EBITDA Exit HK$8.48 HK$13.97 HK$23.87 64
10Y P/E Exit HK$10.42 HK$19.73 HK$35.61 59
Earnings-Based
Graham-Dodd HK$3.35 HK$23.37 HK$32.79 61
Lynch FV HK$12.12 HK$17.32 HK$22.52 59
PEG = 1.0 HK$12.12 HK$17.32 HK$22.52 55
EPV HK$7.76 HK$8.25 HK$8.69 74
Dividend Discount
Gordon GGM HK$0.2400 HK$0.5000 HK$0.7900 64
DDM Multi-Stage HK$0.2400 HK$0.4200 HK$0.5200 64
Multiples
P/E Multiple HK$8.13 HK$10.84 HK$13.55 63
P/S Multiple HK$4.75 HK$6.33 HK$7.91 58
P/B Multiple HK$11.16 HK$14.89 HK$18.61 55
EV/EBIT HK$8.72 HK$10.20 HK$11.67 66
EV/EBITDA HK$8.90 HK$10.43 HK$11.96 67
EV/Revenue HK$7.46 HK$8.81 HK$10.16 54
Asset-Based
NCAV (Graham) HK$2.58 HK$3.91 HK$4.89 54
Growth DCF
Growth DCF HK$7.02 HK$9.22 HK$12.82 77
Rev-Margin DCF HK$8.34 HK$11.56 HK$18.26 70
Economic Profit
Residual Income HK$5.06 HK$5.42 HK$6.25 74
ROIC Compounder HK$8.88 HK$11.51 HK$13.37 70
Growth Earnings
Growth-Adj P/E HK$16.02 HK$22.89 HK$29.76 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 76/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 45
How much profit the company makes from its sales and capital
Quality Growth 93
Are margins and returns getting better?
Cashflow 32
Do the profits arrive as real cash?
Financial strength 95
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 62
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 75
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+127.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+54.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+341.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+250.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−40,981.4% (2020) → 19.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Growth Forecast

A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+34.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +31.9% a year for the price and +7.4% for the forecasts.
Forecast 2026 (sales)+19.4%
Forecast 2027 (sales)+8.0%
Projected 2028 (sales)+7.2%
Projected 2029 (sales)+6.5%
Projected 2030 (sales)+5.7%

Watch 9969, get fair value alerts →

Compare Innocare Pharma Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 76 · Top 25%
Fair Value upside −6.0% · Top 25%
Profitability
Return on equity (12 months) 18.3% · Top 25%
Return on assets 5.8% · Top 25%
Net margin (12 months) 40.6% · Top 25%
Operating margin (12 months) 42.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 150.6% · Top 25%
Dividend yield (12 months) 0.2% · Bottom 25%
Balance sheet
Debt / equity 0.13× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 19.1× · Cheaper than median
P/B 2.15× · Cheaper than median
P/S (12 months) 4.94× · Cheaper than median
Price / free cash flow (fiscal year) 126.9× · Priciest 25%
EV/EBITDA 8.4× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)25 · sector 1
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)73 · sector 0
HEALTH (low debt)94 · sector 96
DIVIDEND (yield)4 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 9969
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 9969
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs 9969
argenx SE ARGX $950.95 $908.40 −4% vs 9969
CSL Limited CSL A$199.55 A$186.49 −7% vs 9969
Moderna, Inc MRNA $215.27 $135.64 −37% vs 9969
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs 9969
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 9969
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs 9969
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 9969

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Innocare Pharma Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Innocare Pharma Ltd Fair Value". https://www.fairvalue-calculator.com/stock/9969

Frequently asked questions

Is Innocare Pharma Ltd (9969) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of HK$10.42 versus a price of HK$11.09, about 6% lower (fairly valued).
What is the fair value of 9969?
Our model-based fair value for Innocare Pharma Ltd is HK$10.42 (as of Nov 14, 2026), built from audited fundamentals. The current price: HK$11.09.
What is the quality score of 9969?
Innocare Pharma Ltd has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Innocare Pharma Ltd (9969)?
Our model-based price target is the fair value of HK$10.42 (as of Nov 14, 2026) from 26 valuation models. Cautious scenario HK$7.75, optimistic scenario HK$12.82. It is a calculation from audited fundamentals, not an analyst target.
What is the Innocare Pharma Ltd stock forecast for 2026?
Our models put fair value at HK$10.42, about 6% lower versus a price of HK$11.09 (fairly valued). Cautious scenario HK$7.75, optimistic scenario HK$12.82. The calculation is refreshed regularly with new filings.
What is the revenue of Innocare Pharma Ltd (9969)?
Innocare Pharma Ltd reported trailing-twelve-month revenue of about 3.4B CNY (latest available figure, as of Nov 14, 2026).
Does Innocare Pharma Ltd pay a dividend?
Innocare Pharma Ltd currently shows a dividend yield of 0.19% relative to its recent price (as of Nov 14, 2026).
How much is the dividend of Innocare Pharma Ltd (9969)?
Innocare Pharma Ltd has a dividend yield of 0.2%.
What growth is priced into Innocare Pharma Ltd (9969)?
For today's price to be fair in a discounted-cash-flow model, Innocare Pharma Ltd would have to grow free cash flow by 34.1 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 341.9 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of 9969 use?
Our models discount Innocare Pharma Ltd at 9.0 %: a base by market capitalisation (mid), damped by beta 0.37, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Innocare Pharma Ltd that is +34.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Innocare Pharma Ltd (9969) delivered so far?
Over the past 5 years revenue at Innocare Pharma Ltd grew 341.9 % a year. The price currently implies free-cash-flow growth of +34.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Innocare Pharma Ltd (9969) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into Innocare Pharma Ltd (+34.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Innocare Pharma Ltd (9969)?
The free-cash-flow yield on the price is 0.79 %: that much free cash flow Innocare Pharma Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Innocare Pharma Ltd (9969)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Innocare Pharma Ltd it is HK$10.42 per share (as of Nov 14, 2026), against a price of HK$11.09. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Innocare Pharma Ltd stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 9969 trades above its calculated fair value: price HK$11.09, fair value HK$10.42, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9969?
No. The price is what the market pays today (HK$11.09); the fair value is what the company's own numbers justify (HK$10.42). For Innocare Pharma Ltd the two are HK$0.6700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Innocare Pharma Ltd worth?
The market values Innocare Pharma Ltd at about HK$19.6B (market capitalisation, as of Nov 14, 2026). Per share that is HK$11.09; our models calculate a fair value of HK$10.42 per share.
What do the bullish and bearish scenarios say about 9969?
Our models span a range for Innocare Pharma Ltd: cautious scenario HK$7.75, base HK$10.42, optimistic HK$12.82 per share (as of Nov 14, 2026, price HK$11.09). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9969?
Innocare Pharma Ltd trades at a price-to-earnings ratio of 19.1 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$10.42 is built from several models across several years. Other multiples: P/B 2.2, P/S 4.9, EV/EBITDA 8.4.
How solid is the balance sheet of Innocare Pharma Ltd (9969)?
Balance-sheet figures for Innocare Pharma Ltd (as of Nov 14, 2026): return on equity 18.3%, debt of 0.13 per unit of equity. They feed the Quality Score of 76/100, which measures business quality independently of the share price.
How far is 9969 from its 52-week high?
Innocare Pharma Ltd trades at HK$11.09, about 30% below its 52-week high of HK$15.83 and 11% above the low of HK$10.02 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of HK$10.42 is for.
Which stocks are comparable to Innocare Pharma Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Innocare Pharma Ltd stock attractive at the current price?
The data as of Nov 14, 2026: price HK$11.09, calculated fair value HK$10.42 (−6%), Quality Score 76/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9969 calculated?
We run Innocare Pharma Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$10.42 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Innocare Pharma Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Innocare Pharma Ltd (9969)?
The closing price on Nov 17, 2026 was HK$11.09. Our model-based fair value is HK$10.42, about 6% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Innocare Pharma Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.

Key figures of Innocare Pharma Ltd

How large is the market capitalisation of Innocare Pharma Ltd (9969)?
The market capitalisation of Innocare Pharma Ltd is HK$19.6B (≈ $2.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Innocare Pharma Ltd (9969)?
The price-to-sales ratio of Innocare Pharma Ltd is 8.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Innocare Pharma Ltd (9969)?
Earnings per share at Innocare Pharma Ltd are HK$0.8689 (price ÷ EPS = P/E 19.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Innocare Pharma Ltd (9969)?
The dividend yield of Innocare Pharma Ltd is 0.2% (payout 2.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Innocare Pharma Ltd (9969)?
The net margin of Innocare Pharma Ltd is 40.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Innocare Pharma Ltd (9969)?
The return on equity (ROE) of Innocare Pharma Ltd is 18.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Innocare Pharma Ltd (9969)?
On an EBIT basis the return on assets of Innocare Pharma Ltd is −3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Innocare Pharma Ltd (9969)?
The operating margin of Innocare Pharma Ltd is 42.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Innocare Pharma Ltd (9969)?
Revenue at Innocare Pharma Ltd is growing 151% versus a year earlier (3y avg +54.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Innocare Pharma Ltd (9969)?
Earnings per share at Innocare Pharma Ltd are growing 500% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Innocare Pharma Ltd (9969) hold?
Innocare Pharma Ltd holds more cash than debt, 3.7B CNY net (balance sheet 30 Sep 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Innocare Pharma Ltd in the live analysis

One click puts Innocare Pharma Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.